Estrogen Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Estrogen Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer [NA]
The study evaluating circulating tumor DNA–based minimal residual disease detection in early-stage breast cancer is currently suspended.
-
CLINICAL_TRIALS other · 2026-03-04Clinical Trial Update: Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial [Phase 3]
A Phase 3 trial evaluating low-dose tamoxifen for invasive breast cancer (LoTam) has been suspended. Sponsored by the Alliance for Clinical …
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer [Phase 2]
A Phase 2 window-of-opportunity trial in premenopausal patients with ER-positive, HER2-negative early breast cancer comparing giredestrant w…
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer [Phase 2]
This Phase 2 trial evaluates pembrolizumab in combination with endocrine therapy and palbociclib for postmenopausal patients with newly diag…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) [Phase 3]
Phase 3 clinical trial update on evaluating giredestrant versus physician's choice of adjuvant endocrine therapy for estrogen receptor-posit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer [Phase 3]
Phase 3 trial comparing Vepdegestrant (ARV-471) plus palbociclib vs letrozole plus palbociclib in ER-positive/HER2-negative advanced breast …
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) [NA]
A prospective Phase 2 study (Oligopro-Breast) is evaluating stereotactic radiotherapy for oligoprogressive, estrogen receptor-positive and H…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Phase 3]
Phase 3 clinical trial update comparing giredestrant plus everolimus to physician's choice endocrine therapy plus everolimus in estrogen rec…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor [Phase 3]
A Phase 3 trial evaluating the combination of fulvestrant and ipatasertib in advanced ER-positive, HER2-negative breast cancer after progres…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy [Phase 2]
Phase 2 clinical trial comparing Replens vaginal moisturizer to intra-vaginal estrogen for vaginal dryness in patients with estrogen recepto…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of fulvestrant and abemaciclib with a fulvestrant run-in for estrogen receptor-positive,…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications [Phase 1]
A Phase 1 clinical trial update describes evaluation of BBI-355 (CHK1 inhibitor) in combination with BBI-825 (RNR inhibitor) for tumors with…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer [Phase 2]
A Phase 2 umbrella trial testing subtype-targeted therapies for estrogen receptor-positive, HER2-negative breast cancer has completed, and r…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) [Phase 2]
Phase 2 randomized CAPELA trial comparing capecitabine plus elacestrant versus capecitabine alone in estrogen receptor–positive breast cance…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor [Phase 2]
Phase 2 clinical trial evaluating a genetically-informed therapy for estrogen receptor-positive breast cancer after CDK4/6 inhibitor treatme…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) [Phase 2]
The NAOMI Phase II trial is evaluating neoadjuvant aromatase inhibitor therapy for estrogen receptor-positive breast cancer. The study is cu…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients [Phase 1, Phase 2]
This clinical trial update indicates that a Phase Ib/II study evaluating QLS1304 in combination with endocrine therapy for advanced ER+/HER2…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC [Phase 1, Phase 2]
A Phase Ib/II clinical trial is evaluating multiple combination therapies with FWD1802 in ER+/HER2- breast cancer and related stages, and is…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC [Phase 2]
This clinical trial update covers a Phase 2 study evaluating sequencing of antibody-drug conjugates in estrogen receptor-positive, HER2-low/…
-
CLINICAL_TRIALS withdrawal · 2025-12-24Clinical Trial Update: Effect of Capivasertib on ctDNA in ER Positive Breast Cancer [Phase 2]
A Phase 2 trial evaluating capivasertib on circulating tumor DNA in estrogen receptor-positive breast cancer has been withdrawn.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer [EARLY_Phase 1]
An early-phase clinical study evaluating FES imaging to optimize tamoxifen therapy in estrogen receptor–positive metastatic breast cancer, i…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Combined Immunotherapies in Metastatic ER+ Breast Cancer [Phase 2]
This clinical trial update notes a Phase 2 study evaluating combined immunotherapies for metastatic estrogen receptor-positive breast cancer…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca [Phase 2]
Phase 2 trial evaluating a once-daily accelerated partial breast irradiation regimen for low-risk, hormone receptor-positive breast cancer; …
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Personalised Disease Monitoring in Metastatic Breast Cancer
This ClinicalTrials.gov entry reports an active but not recruiting study evaluating personalised disease monitoring in metastatic, estrogen …
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating fulvestrant with or without an AKT inhibitor in advanced aromatase inhibitor-resistant estrogen recept…